ReviewCurrent pharmaceutical design2017

Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.

Pei-Pei Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.